Kadmon Holdings Llc (KDMN)
Pay Consultant Gets Prison for Insider Trades in $1.9 Billion Sanofi-Kadmon Deal
An executive pay consultant will spend a year and a day behind bars for insider trading in connection with Sanofi SA’s $1.9 billion acquisition of biotech firm Kadmon Holdings Inc.
Wilson Disease Drugs Market Analysis Growth Challenges, Opportunities and Future Developments to 2029
Kadmon Holdings, Inc. (KDMN) Reports Q3 Loss, Tops Revenue Estimates
Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 3393.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadmon expected to close 4Q 2021 - NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported
Noteworthy Thursday Option Activity: RKT, KDMN, AZO
First Week of June 2022 Options Trading For Kadmon Holdings (KDMN)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGP, ESBK, KDMN, VNE; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Teekay LNG Partners L.P. (NYSE:TGP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Stonepeak for $17.00 in cash per common unit or common unit equivalent. If you are a Teekay LNG shareholder, click here to learn more
SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MDLA, MSON, KDMN, ECHO; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Medallia, Inc. (NYSE: MDLA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo for $34.00 per share in cash.If you are a Medallia shareholder, click here to learn more about your rights and options. Misonix,
Moore Kuehn Encourages KDMN, NXU, JMP, and HTPA Investors to Contact Law Firm
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
INVESTIGATION: Halper Sadeh LLP Investigates HRC, JMP, KDMN, BCML, XONE; Shareholders are Encouraged to Contact the Firm
Lifshitz Law Firm, P.C. Announces Investigation of CXP, HRC, KDMN, and JMP
SHAREHOLDER ALERT: WeissLaw LLP Investigates Kadmon Holdings, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm
